BLK Gene Maturity-Onset Diabetes of the Young Type 11 (MODY11) Genetic Test in UAE | 2,800 AED

Executive Summary & Core Metrics

Precision Molecular Diagnostics for Monogenic Diabetes – BLK Gene Sequencing by NGS

This advanced diagnostic test utilizes Next-Generation Sequencing (NGS) to detect pathogenic variants in the BLK gene, providing a definitive molecular diagnosis for MODY11. The service is clinically overseen by our Consultant Medical Genetics team and processed at our DHA-licensed, ISO-accredited laboratory in Dubai Healthcare City.

Diagnostic Yield: >99.9% sensitivity and specificity for BLK pathogenic variants, including novel discoveries.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Oversight: Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA ID 9294403.
Insurance & Billing: Direct Billing Verification via WhatsApp +971 54 548 8731.
Corporate Lab: DNA Labs UAE | DHA Facility License: 1143.

Test Overview & Methodology

Maturity-Onset Diabetes of the Young Type 11 (MODY11) is a monogenic form of diabetes caused by heterozygous mutations in the BLK gene. It is frequently misdiagnosed as Type 1 or Type 2 diabetes, leading to suboptimal management. Our comprehensive NGS test analyzes the entire coding sequence and splice sites of the BLK gene, providing the molecular clarity needed for precise, personalized treatment strategies such as transitioning from insulin to sulfonylureas.

Feature	DNA Labs UAE BLK MODY11 NGS Test	Standard Alternative (Targeted Genotyping)
Methodology	NGS – Full Gene Sequencing (All Exons & Splice Sites)	PCR-based SNP or Panel – Limited Variants
Diagnostic Yield	≥99.9% for known and novel BLK variants	70–80% (misses rare/large variants)
Turnaround Time	3–4 Weeks	4–6 Weeks
Precision for MODY11	100% Locus Coverage, ACMG Classified	Only hot-spot mutations

Physician Insight & Safety Protocols

"A definitive molecular diagnosis of MODY11 via BLK sequencing is transformative for targeted therapy, often enabling a transition from insulin to sulfonylureas. However, this must always be carefully correlated with the patient's clinical history, family pedigree, and biochemical profile. Any therapeutic changes should be strictly supervised by an endocrinologist to ensure patient safety."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA ID 9294403

Medication Safety Advisory

Do not discontinue or alter prescribed glucose-lowering therapy (insulin, sulfonylureas, or other hypoglycemic agents) based solely on genetic results. Genetic findings must be integrated into a comprehensive diabetes management plan by a qualified specialist to avoid life-threatening complications.

Exclusion Criteria & Contraindications

Patient inability to provide informed consent or refusal of pre-test genetic counseling.
Acute diabetic crisis (e.g., diabetic ketoacidosis, hyperosmolar state) requiring immediate emergency intervention.
Insufficient sample quality or quantity (e.g., severe hemolysis, clotted sample).
Children below 1 year of age require a DHA-approved pediatric geneticist referral for testing.

Patient FAQ & Clinical Guidance

1. What is the clinical benefit of BLK MODY11 testing over standard diabetes tests?

This DNA test identifies the exact genetic mutation causing MODY11, permitting personalized treatment – typically a safe transition from insulin to low-dose sulfonylureas. It also enables cascade screening for at-risk family members. Unlike autoantibody tests that only rule out Type 1 diabetes, NGS of the BLK gene confirms the monogenic etiology, guiding targeted therapy and reducing lifelong medication burden.

2. Can this test be performed for children in the UAE?

Yes, the BLK gene test is permitted for minors with parental consent and a referral from a DHA-approved specialist. Pre- and post-test genetic counseling is mandatory to ensure the family understands the implications of the results. DNA Labs UAE strictly adheres to UAE Federal Laws governing pediatric genetic testing.

3. How do I prepare, and what does the sample collection involve?

Fasting is not required for this genetic test. A simple blood draw (3 ml in an EDTA tube) is collected by our DHA-licensed phlebotomist at your home during an 8 AM – 11 PM window via our VIP mobile phlebotomy service. A pre-test genetic counseling session is scheduled to document a three-generation pedigree, ensuring the most accurate interpretation of your results.

UAE Regulatory & Data Privacy Adherence

This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic data is handled with strict confidentiality and processed in our DHA-licensed facility in Dubai Healthcare City.

Clinical & Logistical Metadata

Test Name	BLK Gene MODY11 Genetic Test (NGS)
Price (AED)	2,800
Turnaround Time	21–28 Days
Sample Type / Matrix	Peripheral Whole Blood (EDTA) or FTA Card
Methodology Used	Next-Generation Sequencing (NGS) – Full Gene Coverage
ICD-10-CM Code	E13.8, Z15.89, Z13.1
LOINC Code	95767-8
DHA Facility License & Lab Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE